Brought to you by the International Journal of Pharmaceutical Compounding FREE TRIAL    FORMULATIONS    MY ACCOUNT 
Compounding This Week Newsletter from www.CompoundingToday.com
Our Compounding Knowledge, Your Peace of Mind
August 7, 2015  |  Volume 12  |  Issue 32
IN THIS ISSUE
 
SUBSCRIPTIONS / INFO
 
CLASSIFIEDS
 
ABOUT COMPOUNDINGTODAY
 
FREE RESOURCES
 
SUBSCRIBER RESOURCES
1-day LAL course designed specifically for compounding pharmacies - Associates of Cape Cod
Receive a free compounding CD with new subscription to IJPC.
Medisca AlpaWash and CopaSil - Compounding Solutions for Wound and Scar Medications
 
Loyd V. Allen, Jr., Ph.d., R.Ph Letter from the Editor
Nominations of Difficult to Compound Drugs to the FDA-PCAC
DRUG NAME DOSAGE FORM NOMINATOR
Advair Diskus� (fluticasone propionate and salmeterol xinafoate) Inhalation Powder GlaxoSmithKline (GSK)
Advair HFA� (fluticasone propionate and salmeterol xinafoate) Inhalation Aerosol GlaxoSmithKline (GSK)
Alprostadil Injectable Auxilium Pharmaceuticals
Ampyra� ER Tablets Acorda Therapeutics
Anoro� Ellipta� (umeclidinium bromide; and vilanterol trifenatate) Inhalation Aerosol GlaxoSmithKline (GSK)
Atropine None Identified Nephron Compounding Center
Avandamet� (rosiglitazone maleate and glimepiride) Tablet GlaxoSmithKline (GSK)
Avandaryl� (rosiglitazone maleate and glimepiride) Tablet GlaxoSmithKline (GSK)
Avandia� (rosiglitazone maleate) Tablet GlaxoSmithKline (GSK)
Avodart� (dutasteride) Capsules GlaxoSmithKline (GSK)
Azithromycin Intravenous Nephron Compounding Center
Baclofen Intrathecal Implantable Pump Mallinckrodt Pharmaceuticals
Beconase AQ� (beclomethasone dipropionate monohydrate) Nasal Spray GlaxoSmithKline (GSK)
Bio-identical hormone Pellets Kenneth Woliner, MD; Gary Donovitz, MD; Leila Martin
Biologic Products Injectable Biotechnology Industry Organization
Breo� Ellipta� (fluticasone furoate and vilanterol trifenatate) Inhalation Powder GlaxoSmithKline (GSK)
Collagenase SANTYL� 250 units/g Topical Ointment Smith & Newphew Inc.
Coreg CR� (carvedilol phosphate) ER Capsule GlaxoSmithKline (GSK)
Diclofenac Sodium Topical Solution Mallinckrodt Pharmaceuticals
Drug Products Subject to a Risk Evaluation and Mitigation Strategy (REMS) with elements to assure safe use (ETASU) None Identified Biotechnology Industry Organization
Drugs Manufactured by Extrusion or Nanotechnology Extrusion/Nanotech AbbVie
Drugs Utilizing Transdermal Drug Delivery Systems None Identified AbbVie
Dry Powder Inhaler (DPI) Products (non-exempt under 503A and 503B) Dry Powder Public Citizen
Enteric-coated Preparations (non-exempt under 503A and 503B) None Identified Public Citizen
Estradiol Oral and Topical Wulf Utian MB BCh, PhD, DSc (Med), FRCOG, FACOG, FICS
Estriol Individual Drug Carolyn Quist, DO, PA
Flonase� (fluticasone propionate) Nasal Spray GlaxoSmithKline (GSK)
Flovent Diskus� (fluticasone propionate) Inhalation Powder GlaxoSmithKline (GSK)
Flovent HFA� (fluticasone propionate) Inhalation Powder GlaxoSmithKline (GSK)
Heparin None Identified Nephron Compounding Center
High Potency Drugs None Identified AbbVie
Human Chorionic Gonadotropin (HCG) Individual Drug Kenneth Woliner, MD
Hyaluronidase None Identified AbbVie
Hygroscopic, Light Sensitive, Temperature-controlled Drug Products None Identified AbbVie
Itraconazole (Sporanox�) Individual Drug Kenneth Woliner, MD
Jalyn� (dutasteride and tamsulosin HCl) Capsules GlaxoSmithKline (GSK)
Kenalog� (Triamcinolone Acetonide) Injectable, Epidural Dennis Haney
Lamictal� (lamotrigine) Chewable Dispersible Tablet GlaxoSmithKline (GSK)
Lamictal� XR (lamotrigine) ER Tablet GlaxoSmithKline (GSK)
Low Dose Drugs None Identified AbbVie
Metered Dose Inhaler (MDI) Products (non-exempt under 503A and 503B) Aerosolized Public Citizen�s Health Research Group
Methylprednisolone Acetate Injectable, Epidural Terri Anderson, Arachnoiditis Society for Awareness and Prevention
Modified Release Drug Products MR Capsules or Tablets AbbVie
Morphine Implantable Pump Mallinckrodt Pharmaceuticals
Narrow Therapeutic Index Drugs None Identified Biotechnology Industry Organization; AbbVie
Nitroglycerin Ointment Ointment Aptalis Pharma US, Inc.
Nonsterile-to-sterile Compounding (non-exempt under 503Aonly) Injectables, Infusions or Implants, Aqueous-based Inhalation Solutions, and Ophthalmic Products Public Citizen�s Health Research Group; Sarah Sellers
Papaverine Injectable Auxilium Pharmaceuticals
Potiga� (ezogabine) Tablet GlaxoSmithKline (GSK)
Products Susceptible to Oxidation None Identified AbbVie
Progesterone Oral and Topical Wulf Utian MB BCh, PhD, DSc (Med), FRCOG, FACOG, FICS
Progesterone with Estradiol Oral and Topical Wulf Utian MB BCh, PhD, DSc (Med), FRCOG, FACOG, FICS
Promacta� (eltrombopag olamine) Tablet GlaxoSmithKline (GSK)
Relenza� (zanamivir) Inhalation Powder GlaxoSmithKline (GSK)
Requip XL� (ropinirole hydrochloride) ER Tablet GlaxoSmithKline (GSK)
Rythmol SR� (propafenone hydrochloride) ER Capsule GlaxoSmithKline (GSK)
Serevent� Diskus� (salmeterol xinafoate) Inhalation Powder GlaxoSmithKline (GSK)
Soriatane� (acitretin) Capsules GlaxoSmithKline (GSK)
Sterile Drugs Injectable AbbVie
Sterile Products for Ophthalmic Use None Identified FaegreBD Consulting
Sustained or Time-release Dosage Forms (non-exempt under 503A and 503B) None Identified Public Citizen�s Health Research Group
Tafinlar� (dabrafenib mesylate) Capsules GlaxoSmithKline (GSK)
Tecfidera� (dimethyl fumarate) ER Capsule Biogen Idec
Testosterone Pellets Abraham Morgentaler; Auxilium Pharmaceuticals; Men�s Health Network
Transdermal Delivery Systems (TDSs) (non-exempt under 503A and 503B) Transdermal Public Citizen
Veltin� (clindamycin phosphate and tretinoin) Gel GlaxoSmithKline (GSK)
Ventolin� HFA (albuterol sulfate) Inhalation-Aerosol GlaxoSmithKline (GSK)
Veramyst� (fluticasone furoate) Nasal Spray GlaxoSmithKline (GSK)
Votrient� (pazopanib) Tablets GlaxoSmithKline (GSK)
Wellbutrin� SR (bupropion hydrochloride) SR Tablet GlaxoSmithKline (GSK)
Zyban� (bupropion hydrochloride) SR Tablet GlaxoSmithKline (GSK)
ER = Extended Release; MR = Modified Release; SR = Sustained Release

Go to http://www.ijpc.com/Webcontent/ for a printable, formatted table.

More information available at:
http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting
Materials/Drugs/PharmacyCompoundingAdvisoryCommittee/UCM449535.pdf

Next week: Proposed Evaluation Criteria to be Used by the FDA PCAC for this List


Loyd V. Allen, Jr., PhD, RPh
Editor-in-Chief
International Journal of Pharmaceutical Compounding
Remington: The Science and Practice of Pharmacy Twenty-second edition

 

News

Benzocaine Otic Warning
Benzocaine is now the target of an FDA warning which says ear drops, with Benzocaine, can lead to dangerous side effects. One death occurred when a baby was given the drops despite warnings not to use in infants under the age of one. Benzocaine is one of six drugs that have been allowed by the FDA to be on the market but were never evaluated for use in ear drops.
http://www.wsfa.com/story/29718652/fda-issues-warning-about-ear-drops-containing-benzocaine

Tweens and Teens and Over-the-counters
According to national surveys, tweens received a failing grade for knowledge about the proper use of over-the-counter (OTC) medicines; only about half knew such medicines can be dangerous when improperly used or mixed with other drugs. Also, parents said they didn't believe their kids could effectively understand the drug facts on labels. Students entering college have had very little classroom instruction regarding OTC medications; most of what they know about OTC products is what they see advertised in the media and what they learn from other people.
http://www.washingtonpost.com/national/health-science/over-the-counter-drug-literacy-a-must-for-tweens-and-teens/2015/08/04/52cf2506-3ac8-11e5-b759-e3c43f009486_story.html

CVS Strips 31 and Express Scripts Strips 20 More Rx Medications from Insurance Coverage
CVS Health Corp, the nation's second-biggest PBM, said that next year it will exclude an additional 31 prescription medicines from insurance coverage, including widely used treatments for diabetes and multiple sclerosis. When drugs are deleted from coverage, patients may have to pay full price for them. PBMs often keep or dump a product depending on whether they can obtain favorable pricing. Express Scripts, the nation's biggest PBM, has said it would boot about 20 additional medicines from its formulary in 2016.
http://www.reuters.com/article/2015/08/05/cvs-health-coverage-idUSL1N10G3HE20150805

Three-Dimensional Printing for Medications
Aprecia Pharmaceuticals has received FDA approval for Spritam, the first FDA-approved drug to use three-dimensional printing technology. Spritam is a formulation of levetiracetam that uses the process to prepare rapidly disintegrating tablets. They are building a new facility to make quick-dissolve, easily ingested formulations of highly prescribed high-dose medications. The process "stitches together multiple layers of powdered medication using an aqueous fluid to produce a porous, water-soluble matrix that rapidly disintegrates with a sip of liquid." The powder-liquid 3DP technology was developed at the Massachusetts Institute of Technology (MIT) in the late 1980s as a rapid-prototyping technique. Aprecia says its technology allows for delivery of a high drug load, up to 1,000 mg, in a single dose. This opens up endless possibilities for personalized medicine. Projected in the future is where a 3-D printer can follow a recipe given by a pharmaceutical company and produce whatever is needed, on the fly from a set of chemical inks, to produce a medication.

(Editor's Note: Sounds almost like compounding!)

http://www.washingtonpost.com/news/to-your-health/wp/2015/08/04/fdas-approval-of-first-3-d-printed-pill-opens-up-endless-possibilities-for-personalized-medicine/

http://www.fiercepharmamanufacturing.com/story/fda-approves-seizure-drug-made-3-d-technology/2015-08-03

 

IJPC Now on Facebook and Youtube

Become a fan of the IJPC Facebook page and share ideas, photos, and keep up to date with the latest compounding information - http://www.facebook.com/IJPCompounding

Learn about the Journal's new multi-media features and view our growing collection of educational and training videos at www.ijpc.com/video or by subscribing to our Youtube channel at https://www.youtube.com/user/IJPCompounding.

 

Did You Know ...

�that when developing a hypothesis or theory when there are insufficient facts, opinions are frequently used? The difficult task is to determine when this occurs.

 

Tip of the Week

As we see in the theme of the Science Channel, "Question Everything"!

 

Looking Back

Substitutes!
Smooth guys sell'em,
Easy marks use 'em,
Well-groomed men,
Always refuse 'em!
     Burma Shave

Copyright 2015
International Journal of Pharmaceutical Compounding, Inc.
122 N Bryant Ave, Edmond OK 73034
Manage my Email:
Subscribe / Un-Subscribe
Comments or Questions:
info@compoundingtoday.com
Reprints & Permissions: Reprints@ijpc.com